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Prediction of Successful Suppression of Sustained Ventricular
Tachyarrhythmias by Serial Drug Testing From Data Derived at the
Initial Electrophysiologic Study
DENNIS L. KUCHAR, MD, FRACP, JEFFREY ROTTMAN, MD, ERIC BERGER, MD,
CHARLES S . FREEMAN, RN, HASAN GARAN, MD, FACC, JEREMY N . RUSKIN, MD, FACC
Boston, Massachusetts
This study investigated whether data available after the
initial electrophysldogie study in patients with sustained
ventricular tachyarrhylhmiu could identify those patients
in whom serial drug testing Is likely to be eficucious, One
hundred six patients with Inducible sustained ventricular
tachyarrhythmla, whose initial study included short-term
drug testing with intravenous procainamWe, were evalu-
ated, The baseline arrhythmia induced (in the absence of all
antiarrhythmic drugs) was monomorphic tachycardia with
a cycle length >200 ms in 81 patients and ventricular Purer
or fibrillation in the remaining 25 patients. After intrave-
nous infusion of procafnamide (1,250 ± 300 mg), a ventric-
ular tachyarrhythada could still be induced in 80 patients
during testing with up to three exlrastimuli . Serial drug
testing with one to four trials of oral conventional and
investigational agents was then undertaken
.
Evaluation of 15 clinical, hemodywnic and eleelrophys-
iologic variables by stepwise logistic regression identified
two independent predictors of successful response to oral
aatiarrhythmic drugs: 1) aonindocibility of ventricular
tachycardia after intravenous procainamide (p < 0 .001),
and 2) left ventricular ejection fraction a40% (p < 0 .05) .
Suppression of sustained ventricular tachyarrhythmias by
antiarrhythmic drugs identified as efficacious by serial pro-
grammed ventricular stimulation studies is associated with a
favorable outcome (1-4). However, the yield of serial drug
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Subgroup analysis combining each of these variables Iden-
tified patients with a high, intermediate or low probability
of Ending a successful oral drug regimen . Patients whose
arrhythmia was suppressed by intravenous procainamlde
had a 100% likelihood (If left ventricular ejection fraction
was ?40%) or an 87% likelihood (if ejection traction was
<40%) of responding to an oral regimen. Patients whose
arrhythmia was still lndaeibie after letravcwuos procaina-
mide and had an ejection fraction ?40% had an interme-
diate likelihood (46%) of oral drug response. Patients with
persistent ventricular tachycardle after Intravenous pro-
cainamidc and an ejection fraction <40% had a low
probability (19%) of successful response to an oral aatl-
arrhythndc regimen.
Hence, patients who are unlikely to benefit from serial
drug testy can be identified with use of s simple algorithm
incorporating the left ventricular ejectleo fraction and the
response to intravenmus procalimmfde at the initial ehx •
trophvsidogic study. Early consideration often Implantable
device or arrhythmia surgery may be appropriate for such
patients .
(JAm Coll
Card '1
1988:12:982)
testing is low for currently used conventional agents as well
as for more recently introduced experimental agents, with
overall suppression rates of 15 to 52% (5-10)
.
In the remain-
ing patients, surgical and catheter ablation, implantable
devices and empiric therapy with amiodarone have become
acceptable therapeutic options (11-14). Identification, early
after their initial evaluation of those patients whose arrhyth-
mia is unlikely to b .- suppressed by drugs could reduce the
period of hospitalization and provide more cost-effective
management. Recent studies (5-7) have suggested that such
patients can be identified on the basis of demographic and
clinical data ; successful drug-induced arrhythmia suppres-
sion was seen particularly in patients without coronary
artery disease, and especially in those without any structural
0735 .1097/951t3.50
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cardiac disease. However, in clinical practice . the majority
of patients referred for electrophysiologic studies have sus-
tained ventricular tachycardia occurring in the setting of
chronic myocardial infarction .
In our initial electrophysiologic evaluation of patients
with induced sustained ventricular tachycardia, we routinely
perform short-term drug testing with intravenous procaina-
mide infusion . It has been suggested (15,16) that a favorable
response to this agent is associated with a high likelihood of
arrhythmia suppression with other oral class I antiarrhyth-
mic drugs . This study was undertaken in an attempt to
identify predictors of successful drug suppression in a series
of patients who underwent serial electrophysiologic testing
with a wide range of antiarrhythmic agents, from information
available after the initial electrophysiologic study, including
the response to intravenous procainamide
.
Methods
Study patients. The study group comprised 106 patients
who underwent comprehensive electrophysiologic testing
for evaluation of documented or suspected spontaneous
ventricular tachycardia or fibrillation unrelated to acute
myocardial infarction . These patients all had inducible sus-
tained ventricular tachyarrhythmias in the absence of anti-
arrhythmic drugs . They constitute a subgroup of patients
who underwent evaluation of the response to programmed
ventricular stimulation before and after infusion of intrave-
nous procainamide at the initial study, among a consecutive
series of patients with inducible ventricular arrhythmias .
These patients represent a distinct study group from those
described in a prior report from our laboratory (7) .
There were 87 men and 19 women with a mean age of 61
years (range 27 to 79) . Based on clinical, echocardiographic,
histologic and angiographic data, the primary cardiac diag-
noses included coronary artery disease (luminal stenosis
w50% in at least one major vessel) in 94 patients (81 with a
history of prior myocardial infarction), congestive cardiomy-
opathy in 6 patients, valvular heart disease in 2 and hyper-
trophic cardiomyopathy, repaired tetralogy of Fallot and
right ventricular dysplasia in I patient each. One patient had
no evidence of structural heart disease with normal right and
left ventricular function and normal right ventricular biopsy
findings. Mean left ventricular ejection fraction determined
from radionuclide ventriculogaphy was 35 ._ 15% (range 10
to 70%). Indications for electrophysiologic study included
out of hospital cardiac arrest in 45 patients and sustained
monomorphic ventricular tachycardia in 45 patients
; the
remaining patients were studied because of syncope (9) or
high grade ventricular ectopic activity (7).
Eketrophysiologicstudy. Patientsunderwentelectrophys-
iologic evaluation in the postabsorplive slate after informed
written consent was obtained . All antiarrhythmic agents
(excluding beta-adrenergic blocking agents and digoxin)
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were discontinued for at least five half-lives before study .
The protocol for programmed ventricular stimulation in .
cluded introduction of up to three extrastimuli during vein
tricular pacing at two basic cycle lengths (600 and 400 ms)
from the right ventricular apex. If ventricular tachycardia
could not be induced with three extrastimuli from the apex,
the catheter was moved to the right ventricular outflow tract
and stimulation repeated at this site . Burst right ventricular
pacing was not performed in this group. Sustained ventric-
ular tachycardia was defined as a ventricular tachyarrhyth-
mia lasting ?30 s or requiring active termination because of
hemodynamic collapse (17). Arrhythmias were subclassified
according to the cycle length of the induced arrhythmia and
the constancy of beat to beat QRS configuration . Ventricular
tachycardia was defined as monomorphic if successive QRS
complexes had a similar configa-ation in all leads without a
change in frontal or horizontal axis >30° from one beat to
another : monomorphic ventricular tachycardia with a cycle
length <_200 ms was defined as ventricular flutter . Ventricu-
lar fibrillation was defined as a sustained polymorphic
arrhythmia, with marked beat to beat variation in configura-
tion and electrocardiographic (ECO) frontal and horizontal
axes. The induced arrhythmia was classified as monomor-
phic if z If successive beats displayed uniform configuration
before degenerating to ventricular fibrillation .
After induction of venlraTdar tachycardia or frbri/larion,
an infusion of inrraveamrs procainamide Was instituted . This
was administered as a loading dose of 16 mg/kg body weight
over 20 min followed by a maintenance infusion of 3 mg/min .
The infusion dose was decreased if significant hypotension
(<90 mm Hg systolic) or marked QRS or QT prolongation
occurred . Repeat programmed ventricular stimulation was
performed approximately 30 min after initiation of the infu-
sion, and blood levels were drawn at the conclusion of the
stimulation protocol. The end point of stimulation after
intravenous drug testing was induction of a sustained ven-
tricular arrhythmia or completion of the protocol with deliv-
ery of three extrastimuli, regardless of The baseline charac-
teristics of ventricular tachycardia induction . Arrhythmia
suppression
during intravenous procainamide thereafter was
defined as inability to initiate ventricular tachycardia . In
addition, we did not consider ventricular tachycardia to be
suppressed by intravenous procainamide if a nonsustained
ventricular arrhythmia > 15 beats was induced . Stimulation
was performed at the right ventricular outflow tract only if
baseline induction of ventricular tachycardia was attained at
this site.
Oral antiurhythmic drug trials. Serial drug testing with
oral antiarrhythmic agents was then performed with the aim
of achieving suppression of ventricular tachycardia in re-
sponse to programmed ventricular stimulation . No set order
of administration of antiarrhythmic agents was used
; drug
selection was determined on the basis of prior drug history,
left ventricular function and patient tolerance
. Testing in
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patients who showed a favorable response to intravenous
procainamide usually began with an oral class I agent . In
addition to conventional class Is agents, drug testing in-
cluded a combination of class Ia and lb agents, Ic agents
(flecainide, encainide, lorcainide, indecainide and propafe-
none) . verapamil . hepridil, sotalol and amiodarone . Many of
the latter agents were administered as part of investigational
drug studies or on compassionate drug use protocols, fre-
quently in patients who had already undergone several drug
trials at other centers .
An effective response to an oral
antiarrhythmic regimen
was defined by
the inability to initiate a sustained ventricular
arrhythmia with the same number of extrastimuli required at
the baseline study, that is, the same level of stimulation at
the right ventricular site as that which induced the ventric-
ular arrhythmia at the baseline study, with use of the
maximal number of extrastimuli of that study as the end
point of the protocol . Responders were discharged on a
maintenance dose of the drug that led to tachycardia sup-
pression
. In patients whose arrhythmia was not suppressed
by antiarrhythmic agents alone (nonresponders), therapeutic
options included therapy with amiodarone (n = 34), trans-
catheter electrical ablation (n = 6) and map-guided endocar
dial resection (n = 2)
. The remainder were treated with
medications that appeared to be beneficial by Halter ambu-
latory (ECU) analysis
. An automatic implantable cardio-
vetter-defibrillator was implanted in seven of the patients
whose arrhythmia was not suppressed by oral antiarrhyth-
mic therapy .
Data analysis. Continuous data are presented as mean
I SD. Unpaired data were compared by two-tailed r test for
continuous variables and by chi-square analysis for compar-
ison of proportions .
The clinical variables tested as univari-
ate predictors of oral drug response were age, gender,
etiology of heart disease, prior myocardial infarction, history
of cardiac arrest and left ventricular ejection fraction (both
absolute and when dichotomized at a value of 40%) . The
baseline electrophysiologic variables included in the univari-
ate analysis were the type of arrhythmia induced and the
number of extrastimuli required for induction at the initial
study and right ventricular effective refractory period
. Also
included
were variables assessing the response to intrave-
nous procainamide : change in refractory period, suppres-
sion of tachycardia, mode of induction and cycle length of
persistently inducible tachycardia and dose and serum level
of procainamide. Univariate predictors with a p value <0 .10
were identified, stepwise logistic regression (18) was per-
formed to construct a multivariate predictor function . This
analysis assigns a coefficient (b) that describes the statistical
weight of variables selected to be independently significant
predictors. Patients with missing values for particular vari-
ables were excluded from univariate analysis of these vari-
ables.
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Results
Electrophyalologle profile at initial electrophysiologic
study
. All 106 patients had sustained ventricular tachycardia
or fibrillation induced at the initial electrophysiologic study .
Monomorphic ventricular tachycardia (with a cycle length
>200 ms) was induced in 81 patients ; the remainder had
rapid ventricular tachyarrhythmias (cycle length X200 ms)
that were either monomorphic (ventricular flutter) or poly-
morphic (ventricular fibrillation)
. The arrhythmia was in-
duced in 6 patients with three extrastimuli and in 100 patients
with two extrastimuli ; in no patient was sustained ventricu-
lar tachycardia induced with only a single extrastimulus .
Electrophysiologic effect of intravenous procainamide
.
The mean dose of procainamide administered was 1,250 t
300 mg (500 to 1,950 mg)
. A modest (10%) increase in right
ventricular effective refractory psaiud was seen (during the
600 ms drive), that is, from 240 ± 23 ms at baseline to 266 ±
28 ms after administration of procainamide (p < 0 .001) .
Ventricular tachycardia (> 15 beats) could All be induced in
80 patients during short-term drug testing
; the mean cycle
length of ventricular tachycardia was increased from 246 ±
63 ms at baseline to 313 ± 81 ms after administration of
procainamide (p < 0.001). Fewer ventricular extrastimuli
were required for induction of ventricular tachycardia in 16
patients and three extrastimuli were required after adminis-
tration of procainamide in 20 patients in whom two extra-
stimuli induced ventricular tachycardia at the baseline study.
In four of six patients their arrhythmia induced initially with
triple extrastimuli was suppressed by intravenous procaina-
mide . A slower ventricular tachycardia was induced after
procainamide in 55 patients and a faster arrhythmia was
induced in 10 .
Table I compares the clinical and electrophysiologic
features of patients whose arrhythmia was suppressed by
intravenous procainamide with the features of those whose
arrhythmia was not suppressed
. Univariate predictors of
arrhythmia suppression were 1) the absence of coronary
artery disease or prior myocardial infarction ; 2) the induc-
tion of ventricular flutter or fibrillation at the initial study
;
and 3) the need to use three extmstimuh at that study to
induce the ventricular arrhythmia .
Results or serial drug testing
. A total of 187 trials of oral
antiarrhythmic agents was performed (mean 1 .7 per patient) .
Patients in whom drug suppression was not successful
underwent an average of 2 .1 drug trials per patient. Serial
drug testing identified 47 drug responders (44% of patients).
A class Is agent alone was successful in suppressing ventric-
ular tachycardia in 18 (46%) of 39 cases and was found to
result in the best overall suppression rate in patients tested
on these agents (Table 2).
Predictors of successful oral drug suppression . 1) Uni-
variate analysis
. Clinical and electrophysiologic variables
identified at the time of initial evaluation are compared for
JACC Vol. 12 . No. 4
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T" 1. Clinical and Electrophysiologic Features of 106 Patients
According to Response to Intravenous Procainamide
Group I represents pollens wbose arrhythmia was suppressed by intra .
venous procainamide ; Group 11 represents patients whose arrhythmia could
still be induced after procainamide . Results are expressed as mcvn ^_ SD .
AAD = antianhythmie drugs ; CL = cycle length : ERP = change in egeclive
refractory period from baseline ; LVEF= ten ventricular ejectionfractin r : NS
= not sigrdficanR VF = ventricularfihrillalion ; VT = ventricular tachycardia.
responders and nonresponders in Table 3. Responders were
characterized by higher left ventricular ejection fraction (p =
0 .0008) and suppression of ventricular tachycardia by pro-
grammed ventricular stimulation after intravenous procaina-
mide (p = 0.0005)
.
In addition, induction of ventricular
flutter or fibrillation (in the absence of antiarrhythmic drugs)
was also associated with successful drug suppression during
serial drug testing.
Table 2. Oral Antiarrhythmic Agents Tested by Serial
Electrophysiotogic Study
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Table 3 . Clinical and Electrophysiologic Features of Responders
to Serial Drug Testing
Abbreviations as in Table 1 .
Among patients whose ventricular tachycardia was still
inducible after intravenous procainamide, there was no
statistically significant difference in the outcome of serial
drug testing between those whose arrhythmia was inducible
with more extrastimuli compared with those in whom it
was induced with the same number of extrastimuli (35
versus 23%, p = NS) or between those patients whose
induced tachycardia was the same and those in whom it was
slower after intravenous procainamide (30 versus 20%
. P =
NS).
2) Multivariate analysis
. Stepwise logistic regression
analysis selected three variables as independently significant
predictors of oral drug suppression : a) inability to induce
ventricular tachycardia with three extrastimuli after intrave-
nous procainamide (b = 3.3, p = 0.0004), b) the absence of
coronary artery disease (b = 0 .9, p = 0.005), and c) a left
ventricular ejection fraction >40% (b = 0 .7, p = 0.013) . A
separate analysis was also performed in the group of
patients
with coronary artery disease. Regression analysis again
identified both the response to intravenous procainamide (b
= 4 .0, p = 0 .0003) and a left ventricular ejection fraction
>40% (b = 0.6, p = 0 .047) as independent predictors
.
Because the response to intravenous prucainamide and
the left ventricular ejection fraction were disc: to variables,
the rate of drug response was caiculated for a subgroup of
the total patient group (big . I). In patients in whom ventric-
ular tachycardia was not inducible after administration
of
procainamide and who
had an ejection fraction >40%, 100%
suppression with oral antiarrhythmic drugs was achieved . In
patients with persistently inducible ventricular tachycardia
Vaagban-Williams
Class a
Response During
Seral Testing
I< S1
Class la 46
Procainamide
25
Quinidine 12
Disopyramide 2
Class lb 3
0
Class Ic 10
10
Class Ilt
Amialarone 38
13
Sota1u1 14 29
Combination therapy
la+lb 64 20
Miscellaneous I8 28
Group I
In = 261
Group II
In = got
p
Value
Age (yr) 60 2
12 60 2 13
NS
Gender ltnrNworeen1 2016 67113 NS
Cardiac disease
Coronary artery disease 20 74 <5 .65
Prior myocardial infarction 16 65 <0.115
Congestive eardiomyopathy 3 3 NS
Cardiac arrhythmia
History of cardiac arrest 10 35 NS
Induced VF/flutter 9 16 <0.05
CL of induced VT
244 <
87 247 2 62 NS
LVEF (9n) 39 x 12 37±14 NS
LVEF < 40% Is 57 NS
Empiric AAD 2.5 2 1.1 2_ .6! 1 .3 NS
Triple extrastimuli 4 2
<
5.05
Pracainamide
ERP after procainamide +24 ± 21 NS+31 ± 21
Dose administered Img) 1 .209 ± 274 1,292 2 273 NS
Serum drug level (µg/m0 10 .7 7 5 .9 9 .1 2 2 .9 NS
No . of oral drugs tested 1 .3 ! 0.8 17 - 1 .0
NS
ltcspomlers
(a = 47)
Nonresponders
In = 591
p
Value
Age lyrl
59 x
12 61 c 12 NS
Gender(malelfenulel 35112
52R NS
Cardiac disease
Coronary artery disease 37 57 NS
Prior
my-dial
infarction 31 50 <0.05
Congestive cardiomyopathy 6 0 <0.05
Cardiac arrhythmia
History of cardiac arrest 21 24 NS
Induced VF :flurter 17 8 <0 .01
Cycle length or
VT
237 z
00 555 --
58
NS
LVEF(9r1 41!14 34-12 <0.005
LVEF < 407, 23 4a <0o01
EmpirK AAD 2.5 7 L2 2.6 ± 1.2 NS
Triple extrastimuli 4 2 N:.
Response to intravenous
procainamide
No VT induced 27 0
<0.001
VT harder to induce
7
13 NS
Slower VT induced
16
38 NS
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Figure 1. Likelihood of response to an oral antiarrhythmic regimen
during serial drug testing . Shown here is the influence of response to
intravenous (IV) procainamide during initial electrophysiologic
study and left ventricular ejection fraction (LVEF).
during drug testing with intravenous procainamide and who
had left ventricular dysfunction, a successful oral anti-
arrhythmic regimen was found in only 19% .
Response to individual antlurrhythmic drugs. Although all
patients were not tested with the same antiarrltylhmic regi-
men during serial drug evaluation, patients in whom ventric-
ular tachyarrhythmia was suppressed by intravenous procai-
namide at the initial study were more likely to respond
favorably to oral class IS agents (71 versus 17%, p < 0
.005),
to amiodarone (75 versus 6%, p < 0.005) and to combina-
tions of class la and lb agents (75 versus 17%, p < 0 .05) than
were those whose arrhythmia was persistently inducible . Of
7 patients whose arrhythmia was suppressed by intravenous
ptocanamide but who did not respond to an oral class In
agent, 6 (86%) were subsequently found to respond to a drug
of a different functional class or a drug combination ; this
compared with 3 (19%) of 16 patients whose arrhythmia was
not suppressed by intravenous procainamide and who then
subsequently failed to respond to an oral class la agent (p <
0.05) .
Discussion
Serial antiarrhythmic drug testing guided by electrophys-
iologic studies is a valuable technique for predicting a
successful outcome in patients who are found to have their
tachycardia suppressed by their treatment regimen . How-
ever, poor results have accompanied attempts to suppress
ventricular tachycardia induction in patients with coronary
JACC Vol . 12, No. 4
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artery disease and prior myocardial infarction ; recently
reported suppression rates for individual antiarrhythmic
agents have ranged between 10 and 45% (19-22), and overall
suppression rates between 15 and 52% (5-7,
16) . In addition,
serial drug testing is time consuming, expensive and uncom-
fortable for patients, often requiring multiple invasive pro-
cedures and defibrillations and exposure to potential adverse
drug effects (23) . It would therefore be desirable to devise an
objective means of stratifying patients soon after their initial
evaluation by their likelihood of benefit from this technique .
This retrospective study suggests that an assessment of
left ventricular function and the response to acute testing
with intravenous procainamide during the initial electrophys-
iologic study together enable identification of patients with
high and low probabilities of responding to an oral anti-
arrhythmic drug regimen .
Predictive value of response to intravenous procainamide .
Previous investigators (15,16) have shown that a beneficial
response to procainamide is often associated with a similar
response to other related antiarrhythmic agents, particularly
class [a agents. In this study we examined the relations
among several electrophysiologic variables and arrhythmia
suppression by serial drug testing with conventional or
investigational drugs . In a significant number of patients
whose arrhythmias were suppressed by intravenous procai-
namide but did not respond to oral procainamide or another
class I agent, suppression was seen with the use of oral
antiarrhythmic agents of a different class . This failure to
reproduce the response to intravenous procainamide may be
related to disparate serum drug levels attained with the oral
preparation and a need for fairly high doses of procainamide
to suppress ventricular tachycardia
(25) .
In attempting to
achieve similar serum levels to those attained after intrave-
nous administration, patient intolerance is a frequent prob-
lem necessitating reduction of the dose or addition of a
second agent . Despite the currently accepted classification
of antiarrhythmic drugs on the basis of their differing cellular
electrophysialogic effects, the response to intravenous pro-
cainamide was seen to be predictive of the response to other
currently available antiarrhythmic agents, extending the
association previously shown among the class I agents .
This study demonstrates that if intravenous procainamide
leads to short-term suppression of ventricular tachycardia
induction, serial oral drug testing should be performed, lvith
a high expectation of successful drug response . However,
response to oral procainamide cannot be presumed and
electrophysiologic testing with this agent should be per-
formed. In patients with moderate or severe left ventricular
dysfunction whose arrhythmia was persistently inducible at
the initial study after intravenous procainamide, the yield of
further serial drug testing with electrophysiologic studies
was low ; that is, 80% of patients in this category had
persistently inducible tachycardia on all medications tested .
These latter patients, after being identified at the initial
JACC Vol . 12. No. 4
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evaluation, might have been spared the discomfort and
expense of serial drug testing . In patients with inducible
ventricular tachycardia after intravenous procainamide and
with only mild left ventricular dysfunction, serial drug test-
ing may still be of sufficient yield to justify its routine
application.
The reason for the strong
predictive
power of left ventric-
ularfunction in predicting drug response is not immediately
apparent. Recent studies (5,6,16) have demonstrated the
negative association of left ventricular aneurysm and coro-
nary artery disease with suppression of ventricular tachycar-
dia . Furthermore, patients with a low ejection fraction have
fewer drug options because, in many of them, the anti-
arrhythmic agents have significant negative inotropic and
proarrhythmic effects . Our data suggest that the degree of
left ventricular dysfunction is a major determinant of drug
responsiveness ; in patients with coronary artery disease and
prior myocardial infarction, the ejection fraction remained
an independent predictor of drug response.
Alternatives to serial electrophysiologle-pharmacologic
testing. With consideration of these two variables, available
early in a patient's hospitalization, it may be possible to
stratify patients into distinct groups with differing probabil-
ities of a successful response to oral antiarrhythmic therapy .
Swerdlow et al . (5) suggested that patients identified as
having a low likelihood of suppression by oral drug therapy
based on electrophysiologic testing should be evaluated
using another modality, such as the use of ambulatory ECG
(Hotter) monitoring. Recent data (26), however, suggest that
only a small minority of patients presenting with spontane-
ous sustained ventricular tachycardia have sufficient ventric-
ular ectopic activity recorded to enable an objective assess-
ment of antiarrhythmic effect ; furthermore, suppression of
ectopic activity on Halter monitoring is associated with an
unacceptable rate of spontaneous arrhythmia recurrence
(27). In patients evaluated by Halter monitoring, a recur-
rence rate of ventricular tachycardia of 50% was observed
over a follow-up period of up to 2 years compared with 20%
in the group evaluated by electrophysiologic testing . Al-
though these results represent only a small population,
further alternatives of management are limited . The empiric
use of amiodarone has been advocated by some groups (14)
in the light of data demonstrating a lack of association
between outcome and the results of el° .trophysiologic test-
ing
. However, our data suggest that the suppression of
induced ventricular tachycatdia by ?otravenous procaina-
mide is predictive for anriodarone as well as for class I
agents, although testing within 10 to 14 days of initiating
therapy may underestimate the clinical efficacy of this drug
(28) . With respect to continuing the patient on treatment
with a conventional antiarrhythmic agent that does not
suppress ventricular tachycardia, data have overwhelmingly
°flown that this practice is associated with a poor long-term
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outcome. Therefore, it may he reasonable to progress to a
nonpharmacologic approach in such patients .
Our overall suppression rate of 44% is somewhat higher
than that reported by other groups . We have defined the end
point of stimulation during serial drug testing as that number
of extrastimuli required at the baseline study to initiate
ventricular tachycardia . This is based on the favorable
outcome noted in our patients when these criteria were
adopted (3 .7) .
Limitations of study. The major limitation of this study is
the lack of uniformity of drug treatment during serial testing .
resulting in an inability to make strong conclusions about the
comparative predictability of subsequent drug responses . A
prospective study with a uniform protocol for drug testing
may allow a more meaningful comparison of drug response ;
however, because of the likelihood of drug intolerance and
consideration of patients with poor left ventricular function,
the drug regimens for each patient will always need to be
individualizes . In this retrospective study, there was a bias
towl.rd use of a class la drug as the first agent if short-term
intravenous testing with procainamide was successful in
suppressing tachycardia. Conversely, in the interest of re-
ducing the number of drug trials and the patient's hospital
stay, a class la agent was usually omitted or combined with
a class lb agent as the first serial drug evaluation in patients
in whom intravenous procainamide was unsuccessful .
Patients with a ventricular tachycardia that was induced
by three exirastimuti at the baseline study had a high rate
(g0%) of suppression after intravenous procainamide
. This
may reflect a consequence of the stimulation protocol, which
involved stimulation during short-term drug testing to a
maximum of three extrastimuli . The use of an additional
extrastimulus could conceivably have led to a lower suppres-
sion rate .
Ideally, at least one drug from each class in addition to
combinations of these agents should be tested before a
patient's arrhythmia is deemed to be truly drug refractory . In
our series of patients, the mean number of drug tests per
patient was relatively low. This is, at least in part, a
reflection of the group of patients seen at a tertiary care
institution where numerous pharmacologic options had al-
ready been explored at another hospital before our eke-
trophysiologic evaluation.
Clinical implleatlo s
. The results of this study suggest a
new method for objectively classifying patients into groups
with a high and low likelihood of successful response to oral
antiarrhythmic therapy on the basis of the initial ei,
:trophys-
iologic testing. Such a classification could be
useful in
identifying patients unlikely to benefit from serial drug
testing in whom an early
decision to proceed with therapeu-
tic alternatives such as implantation of a defibrillator or
performacce of a map-guided ablative procedure could be
made soon after the initial electrophysiologic evaluation .
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